Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Neurodegenerative Disease Market Size During 2025–2029?
The neurodegenerative disease market has experienced robust expansion over recent years. It is anticipated to expand from $52.3 billion in 2024 to $57.23 billion in 2025, progressing at a compound annual growth rate (CAGR) of 9.4%. This historical growth can be credited to factors including improved diagnostic capabilities, an increasing need for symptomatic treatments, a surge in clinical trial endeavors, the growth of public-private partnerships, and the escalating load of unfulfilled medical needs.
The neurodegenerative disease market is projected to experience robust expansion in the coming years. It is anticipated to reach $81.23 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.2%. This growth throughout the forecast period is driven by factors such as continuous advancements in gene and cell therapy, the increasing adoption of digital biomarkers, a rise in precision medicine approaches, a burgeoning pipeline of disease-modifying drugs, and the escalating use of artificial intelligence in neurology. Significant trends during this period are set to include improvements in neuroimaging techniques, sophisticated drug delivery systems aimed at brain targeting, the creation of personalized treatment strategies, innovation in biomarker discovery, and progress in gene editing technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp
What Are The Top Growth Drivers Impacting The Neurodegenerative Disease Market Outlook?
The expansion in research and clinical investigations is anticipated to drive the advancement of the neurodegenerative disease market in the future. Clinical trials are defined as investigative studies carried out involving human subjects to assess the safety, effectiveness, and possible adverse reactions of novel therapies, medications, or medical instruments. This growth in research and clinical trials stems mainly from the growing need for new therapeutic options to meet changing healthcare requirements and enhance results for patients. Clinical trials provide essential data on the safety and efficacy of emerging treatments, thereby bolstering neurodegenerative disease research, accelerating therapeutic progress, and bettering patient outcomes. As an illustration, in November 2023, a report from the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, indicated a modest 4.3% increase in the total annual industry clinical trials launched in the UK, climbing from 394 trials in 2021 to 411 in 2022. Consequently, the surge in research and clinical trials is predicted to boost the expansion of the neurodegenerative disease market.
How Is The Neurodegenerative Disease Market Segmented?
The neurodegenerative disease market covered in this report is segmented –
1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis
2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types
3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospital, Retail, Online
Subsegment:
1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism
2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype
3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)
4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease
5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)
What Are The Major Trends Driving The Growth Of The Neurodegenerative Disease Market?
Major companies operating in the neurodegenerative disease market are actively developing innovative products, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, with the aim of boosting treatment accuracy, enhancing disease-modifying outcomes, and elevating patient quality of life. Next generation adaptive deep brain stimulation (aDBS) systems are sophisticated neurostimulation devices built to deliver real-time, personalized therapy for Parkinson’s disease. They achieve this by dynamically adjusting stimulation parameters based on neural feedback, thereby optimizing therapeutic benefits and minimizing side effects to improve patient results. For instance, in February 2025, Medtronic, a US-based medical technology company, obtained approval from the U.S. Food and Drug Administration (USFDA) for the world’s first adaptive deep brain stimulation (aDBS) system intended for Parkinson’s disease. This specific approval was for the premarket approval (PMA) application concerning the Percept RC neurostimulator, which integrates BrainSense technology to automatically adjust therapy in response to a patient’s brain signals. The system has been clinically validated to offer symptom alleviation for patients with advanced Parkinson’s disease, marking a notable advancement in personalized neuromodulation therapies.
Which Leading Companies Dominate The Neurodegenerative Disease Market Share?
Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report
Which Region Is Expected To Witness The Fastest Growth In The Neurodegenerative Disease Market?
North America was the largest region in the neurodegenerative disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Neurodegenerative Disease Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24618&type=smp
Browse Through More Reports Similar to the Global Neurodegenerative Disease Market 2025, By The Business Research Company
Rare Neurological Disease Treatment Global Market Report 2025
Degenerative Disc Disease Treatment Global Market Report 2025
Neurological Disorder Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model